AMP-activated protein kinase (AMPK) as a potential therapeutic target independent of PI3K/Akt signaling in prostate cancer

Oncoscience

Volumn 1, Issue 6, 2014, Pages 446-456

  Choudhury, Yashmin ^a,b,c   Yang, Zichu ^a   Ahmad, Imran ^a,b   Nixon, Colin ^b   Salt, Ian P ^a   Leung, Hing Y ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^c ASSAM UNIVERSITY   (India)

Author keywords

5 aminoimidazole 4 carboxamide riboside (AICAR); A 769662; AMP activated protein kinase (AMPK); PI3K; Prostate cancer

Indexed keywords

EID: 84921348845     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.49     Document Type: Article

References (29)

1. Hardie DG. AMP-activated protein kinase: a cellular sensor with a key role in metabolic disorders and in cancer. Biochem Soc Trans. 2011; 39(1): 1-13.
2. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Mäkelä TP, Alessi DR, Hardie DG. Complexes between the LKB1 tumor suppressor, STRADalpha/beta and MO25alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol. 2003; 2(4): 28.
3. Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, Edelman AM, Frenquelli BG, Hardie DG. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2005; 2(1): 9-19.
4. O' Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature. 2013; 493(7432): 346-55.
5. Hawley SA, Ross FA, ChevtzoffC, Green KA, Evans A, Fogarty S, Towler MC, Brown LJ, Ogunbayo OA, Evans AM, Hardie DG. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. 2010; 11(6): 554-65.
6. Brown KA, Samarajeewa NU, Simpson ER. Endocrinerelated cancers and the role of AMPK. Mol Cell Endocrinol. 2013; 366(2): 170-9.
7. Vazquez-Martin A, Oliveras-Ferraros C, Lopez-Bonet E, Menendez JA. AMPK: Evidence for an energy-sensing cytokinetic tumor suppressor. Cell Cycle. 2009; 8(15): 3679-83.
8. Nakano A, Kato H, Watanabe T, Min KD, Yamazaki S, Asano Y, Seguchi O, Higo S, Shintani Y, Asanuma H, Asakura M, Minamino T, Kaibuchi K, Mochizuki N, Kitazake M, Takashima S. AMPK controls the speed of microtubule polymerization and directional cell migration through CLIP-170 phosphorylation. Nat Cell Biol. 2010; 12(6): 583-90.
9. Shanware NP, Bray K, Abraham RT. The PI3K, metabolic, and autophagy networks: interactive partners in cellular health and disease. Annu Rev Pharmacol Toxicol. 2013; 53: 89-106.
10. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay N. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem. 2005; 280(37): 32081-9.
11. Tao R, Gong J, Luo X, Zang M, Guo W, Wen R, Luo Z. AMPK exerts dual regulatory effects on the PI3K pathway. J Mol Signal. 2010; 5(1): 1.
12. Hawley SA, Ross FA, Gowans GJ, Tibarewal P, Leslie NR, Hardie DG. Phosphorylation by Akt within the ST loop of AMPK-1 downregulates its activation in tumour cells. Biochem J. 2014; 459(2): 275-87.
13. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006; 6(9): 729-34.
14. Memmott RM, Dennis PA. Akt-dependent and-independent mechanisms of mTOR regulation in cancer. Cell Signal. 2009; 21(5): 656-64.
15. Jose C, Hébert-Chatelain E, Bellance N, Larendra A, Su M, Nouette-Gaulain K, Rossignol R. AICAR inhibits cancer cell growth and triggers cell-type distinct effects on OXPHOS biogenesis, oxidative stress and Akt activation. Biochim Biophys Acta. 2011; 1807(6): 707-18.
16. Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H, Hyduke DR, Collins BT, Gagnon G, Kallakury B, Kumar D, Brown ML, Fornace A, Dritschilo A, Collins SP. AMPactivated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther. 2009; 8(4): 733-41.
17. Valster A, Tran NL, Nakada M, Berens ME, Chan AY, Symmons M. Cell migration and invasion assays. Methods. 2005; 37(2): 208-215
18. Chen Z, Wang T, Cai L, Su C, Zhong B, Lei Y, Xiang AP. Clinicopathological significance of non-small cell lung cancer with high prevalence of Oct-4 tumor cells. J Exp Clin Cancer Res. 2012; 31: 10.
19. Viollet B, Horman S, Leclerc J, Lantier L, Foretz M, Billaud M, Giri S, Andreelli F. AMPK inhibition in health and disease. Crit Rev Biochem Mol Biol. 2010; 45(4): 276-95.
20. Jung SN, Park IJ, Kim MJ, Kang I, Choe W, Kim SS, Ha J. Down-regulation of AMP-activated protein kinase sensitizes DU145 carcinoma to Fas-induced apoptosis via c-FLIP degradation. Exp Cell Res. 2009; 315(14): 2433-41.
21. Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-Aminoimidazole-4-carboxamide ribonucleoside a specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem. 1995; 229: 558-65.
22. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JSC, Alessi DR, Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007; 408: 297-315.
23. Liu X, Chhipa RR, Nakano I, Dasgupta B. The AMPK inhibitor Compound C is a potent AMPK-independent antiglioma agent. Mol Cancer Ther. 2014; doi: 10.1158/1535-7163.
24. Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H, Hyduke DR, Collins BT, Gagnon G, Kallakury B, Kumar D, Brown ML, Fornace A, Dritschilo A, Collins SP. AMPactivated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther. 2009; 8(4): 733-41.
25. Xiang X, Saha AK, Wen R, Ruderman NB, Luo Z. AMPactivated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun. 2004; 321(1): 161-7.
26. Motoshima H, Goldstein BJ, Igata M, Araki E. AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol. 2006; 574: 63-71.
27. Hochegger H, Takeda S, Hunt T. Cyclin-dependent kinases and cell-cycle transitions: does one fit all? Nat Rev Mol Cell Biol. 2008; 9(11): 910-16.
28. Grünwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. 2002; 62(21): 6141-5.
29. Göransson O, McBride A, Hawley SA, Ross FA, Shpiro N, Foretz M, Viollet B, Hardie DG, Sakamoto K. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J Biol Chem. 2007; 282(45): 32549-60.